Physician profile
Paul Lin
NPI 1114972254
$43,120.62
in general payments reported to CMS, 2019-2025
80 companies · $6,101 in 2025
The $6,101 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,902 · 2021: $4,018 · 2022: $5,479 · 2023: $6,186 · 2024: $4,642 · 2025: $6,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $1,679 · Travel and Lodging: $947 · Gift: $20.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,282.46 |
| Education | $1,679.17 |
| Travel and Lodging | $946.73 |
| Gift | $20.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $6,873.65 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Dova Pharmaceuticals | $4,082.20 | 2019-2021 | |
| US Oncology Corporate, INC. | $2,762.59 | 2022-2023 | |
| Pfizer INC. | $2,261.36 | 2019-2025 | |
| Incyte Corporation | $1,997.33 | 2019-2025 | Jakafi, Jakafi, Niktimvo |
| Astrazeneca Pharmaceuticals Lp | $1,997.31 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Seagen INC. | $1,724.45 | 2019-2025 | Tukysa, Adcetris, Padcev |
| Merck Sharp & Dohme LLC | $1,717.17 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Genentech USA, INC. | $1,655.97 | 2019-2024 | Venclexta, Phesgo, Lunsumio |
| Janssen Biotech, INC. | $1,536.06 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Genzyme Corporation | $1,413.92 | 2019-2025 | |
| Lilly USA, LLC | $1,379.26 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $1,323.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,160.98 | 2019-2025 | Opdivo, Krazati, Augtyro |
| Eisai INC. | $1,003.69 | 2019-2025 |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $975.26 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Daiichi Sankyo INC. | $795.07 | 2020-2025 | Injectafer, Enhertu, Datroway |
| Abbvie INC. | $687.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $567.89 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $454.18 | 2020-2025 | Xtandi, Padcev, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $429.18 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Exelixis INC. | $415.04 | 2019-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $392.28 | 2021-2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $333.43 | 2020-2025 | |
| Pharmaessentia USA Corporation | $316.75 | 2022-2025 | Besremi |
| Array Biopharma INC | $308.08 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.56 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $295.06 | 2019-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $247.48 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $199.90 | 2023-2024 | |
| Sobi, INC | $199.58 | 2022-2025 | |
| Puma Biotechnology, INC. | $180.59 | 2019-2023 | |
| Azurity Pharmaceuticals, INC. | $174.56 | 2024-2025 | Danziten, Vivimusta |
| Emd Serono, INC. | $170.55 | 2020-2025 | Bavencio |
| Tempus Ai, INC | $148.96 | 2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $132.31 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Amag Pharmaceuticals, INC. | $131.36 | 2019 | |
| Global Blood Therapeutics, INC. | $121.80 | 2020-2022 | |
| Mirati Therapeutics, INC. | $120.73 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $109.79 | 2024-2025 | Orserdu |
| Gilead Sciences, INC. | $108.57 | 2019-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $108.21 | 2019-2024 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $107.84 | 2022-2025 | Monoferric, Cosela |
| Amneal Pharmaceuticals LLC | $106.03 | 2024-2025 | Neulasta, Avastin, Neupogen |
| Verastem, INC. | $101.38 | 2019-2020 | |
| Foundation Medicine, INC. | $101.29 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $94.66 | 2021-2025 | Onivyde, Somatuline Depot |
| Dendreon Pharmaceuticals LLC | $91.74 | 2024-2025 | Provenge |
| Adc Therapeutics America, INC. | $78.60 | 2024-2025 | |
| Beigene USA, INC. | $75.10 | 2023-2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $73.66 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $63.67 | 2024-2025 | |
| Kite Pharma, INC. | $63.42 | 2023 | Yescarta |
| Taiho Oncology, INC. | $55.05 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $51.75 | 2024-2025 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $51.28 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $49.16 | 2019-2025 | Pyrukynd |
| Kyowa Kirin, INC. | $49.06 | 2023-2025 | Poteligeo |
| Caris Mpi, INC. | $46.90 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $45.81 | 2025 | Tevimbra, Brukinsa |
| Mylan Institutional INC. | $42.67 | 2019 | |
| Sandoz INC. | $38.78 | 2019-2020 | |
| Tg Therapeutics, INC. | $37.00 | 2021 | |
| Fennec Pharmaceuticals, INC. | $34.88 | 2025 | Fyarro |
| Menarini Silicon Biosystems, INC. | $33.66 | 2025 | |
| Organon LLC | $31.03 | 2022 | |
| Spectrum Pharmaceuticals INC. | $28.68 | 2024-2025 | Rolvedon |
| Legend Biotech USA INC. | $24.78 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $24.28 | 2021 | |
| Abbott Laboratories | $23.70 | 2021 | |
| Genmab U.S., INC. | $23.26 | 2024 | Epkinly |
| Immunocore Limited | $22.45 | 2025 | Kimmtrak |
| Iovance Biotherapeutics, INC. | $20.80 | 2025 | Amtagvi |
| Napo Pharmaceuticals INC | $19.75 | 2025 | Gelclair Concentrated Oral Gel |
| Novocure INC. | $19.73 | 2025 | Optune Gio |
| Sun Pharmaceutical Industries INC. | $18.48 | 2025 | |
| Octapharma USA, INC. | $17.15 | 2022 | |
| Karyopharm Therapeutics INC. | $17.14 | 2023 | Xpovio |
| Tolmar Pharmaceuticals, INC. | $14.54 | 2021 | |
| Pharmaand Gmbh | $10.95 | 2025 | Rubraca |
Drugs and devices associated with these payments
Keytruda $882Jakafi $710Sarclisa $634Reblozyl $547Jaypirca $543Erleada $467Verzenio $464Tagrisso $414Venclexta $364Elrexfio $342Enhertu $328Tukysa $325Lenvima $318Adcetris $310Xtandi $302Lynparza $289Injectafer $284Bosulif $281Ibrance $274Besremi $251Braftovi $250Opdivo $241Mektovi $231Cabometyx $225Pluvicto $217Lutathera $208Jevtana $191Libtayo $190Imbruvica $190Ojjaara $184Carvykti $178Comirnaty $170Padcev $169Zejula $167Jemperli $167Orgovyx $167Krazati $166Epkinly $164Lorbrena $164Rybrevant $163Pomalyst $159Xt Cdx $149Vonjo $144Nubeqa $130Paxlovid $116Zepzelca $113Danziten $110Orserdu $110Niktimvo $109Retevmo $108Rezlidhia $107Tavalisse $107Talzenna $103Akeega $98.85Xofigo $94.92Provenge $91.74Promacta $89.17Fruzaqla $83.92Tivdak $82.59Welireg $81.25Ninlaro $75.41Darzalex $73.70Opdualag $70.64Avastin $67.82Neupogen $67.82Neulasta $67.82Kisqali $67.16Cablivi $66.40Vivimusta $64.23Fotivda $63.67Tevimbra $62.28Scemblix $61.82Elitek $58.88Brukinsa $58.63Besponsa $58.03Oxbryta $56.12Lonsurf $55.05Inqovi $55.05Xalkori $54.99Datroway $54.44Tecvayli $53.98Onivyde $52.55Enjaymo $51.89Clonoseq $51.75Zynlonta $51.35Poteligeo $49.06Tibsovo $48.97Elahere $47.78Mi Cancer Seek $46.90Calquence $44.95Augtyro $43.19Tasigna $42.79Phesgo $41.10Monoferric $40.78Yescarta $40.03Wayrilz $39.55Alymsys $38.21Vitrakvi $35.15Stivarga $35.15Fyarro $34.88
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.